

**HHS PUBLIC ACCESS**

Author manuscript

Addict Behav. Author manuscript; available in PMC 2016 October 01.

Published in final edited form as:

Addict Behav. 2015 October ; 49: 1–6. doi:10.1016/j.addbeh.2015.05.007.**Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users****Lian-Yu Chen, M.D., PhD^{a,b}, Rosa M. Crum, M.D., M.H.S.^{a,c,d}, Eric C. Strain, M.D.^c, Silvia S. Martins, M.D., PhD^e, and Ramin Mojtabai, M.D., MPH, PhD.^{a,c}**^aDepartment of Mental Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, 7th floor, Baltimore, MD 21205^bTaipei City Psychiatric Center, Taipei City Hospital, No.309, Songde Rd., Xinyi Dist., Taipei City, Taiwan.^cDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive Baltimore, MD 21224^dDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street W6035, Baltimore, MD 21205^eDepartment of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th street, Rm. 509, New York, NY 10032**Abstract****Objectives**—There are growing concerns about nonmedical use of ADHD stimulants among adolescents; yet, little is known whether there exist heterogeneous subgroups among adolescents with nonmedical ADHD stimulant use according to their concurrent substances use.**Methods**—We used latent class analysis (LCA) to examine patterns of past-year problematic substance use (meeting any criteria for abuse or dependence) in a sample of 2,203 adolescent**Address correspondence to:** Lian-Yu Chen, M.D., PhD Taipei City Psychiatric Center, Taipei City Hospital, General Psychiatry Department No.309, Songde Rd., Xinyi Dist., Taipei City, Taiwan lianyu0928@gmail.com 886-2-2726-3141.**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.**Contributor's Statement:**

Lian-Yu Chen: Dr. Chen conceptualized and designed the study, conducted the analyses, drafted the initial manuscript, and approved the final manuscript as submitted. Ramin Mojtabai, Rosa M. Crum, Silvia S. Martins and Eric C. Strain: Drs. Mojtabai, Crum, Strain and Mojtabai interpreted the study results, reviewed and revised the manuscript, and approved the final manuscript as submitted.

Financial disclosure:

Dr. Mojtabai has received consulting fees from Lundbeck Pharmaceuticals. Dr. Strain has received consulting fees for medical-legal cases, and from The Oak Group, Reckitt Benckiser Pharmaceuticals, DemeRx Pharmaceuticals, Zogenix Pharmaceuticals, and Jazz Pharmaceuticals. Dr. Martins has received consulting fees from Purdue Pharma. Other authors declare they have no conflicts of interest.

Conflict of Interest Disclosures:

All authors declare they have no conflicts of interest relevant to this study.

Acquisition of data:

The data reported herein come from the 2006–2011 National Survey of Drug Use and Health (NSDUH) public data files available at the Substance Abuse and Mental Health Data Archive and the Inter-university Consortium for Political and Social Research, which are sponsored by the Office of Applied Studies, Substance Abuse and Mental Health Services Administration.

participants from the National Surveys on Drug Use and Health 2006–2011 who reported past-year nonmedical use of ADHD stimulants. Multivariable latent regression was used to assess the association of socio-demographic characteristics, mental health and behavioral problems with the latent classes.

Results—The model fit indices favored a four-class model, including a large class with frequent concurrent use of alcohol and marijuana (*Alcohol/Marijuana* class; 41.2%), a second large class with infrequent use of other substances (*Low substance* class, 36.3%), a third class characterized by more frequent misuse of prescription drugs as well as other substances (*Prescription drug+* class; 14.8%), and finally a class characterized by problematic use of multiple substances (*Multiple substance* class; 7.7%). Compared with individuals in *Low substance* class, those in the other three classes were all more likely to report mental health problems, deviant behaviors and substance abuse service use.

Conclusions—Adolescent nonmedical ADHD stimulants users are a heterogeneous group with distinct classes with regard to concurrent substance use, mental health and behavioral problems. The findings have implications for planning of tailored prevention and treatment programs to curb stimulant use for this age group.

Keywords

ADHD stimulants; Substance abuse; Deviant behaviors; Latent class analysis

1. Introduction

Nonmedical use of prescription stimulants, especially stimulants prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), has received increased research attention in the past decade.¹⁻⁴ These stimulants, including methylphenidate and mixed salts amphetamines, are classified as schedule II substances in the US Controlled Substances Act (CSA) due to their high abuse potential.⁵

Past research has reported an increase in nonmedical prescription stimulant use among young adults and adolescents.⁶⁻¹² According to data from the Monitoring The Future (MTF) survey, past-year nonmedical use of methylphenidate in high school seniors increased from 0.5% in 1995 to 2.5% in 2002.¹⁰ In another high school survey, 4.5% of students reported using prescription stimulants nonmedically in their lifetime, with 23.3% reporting being approached to sell, give, or trade these drugs.¹² Emergency room visits involving ADHD stimulants tripled in the period between 2005 and 2010,¹³ highlighting the health burden of nonmedical use of these medications.

Evidences supported that nonmedical ADHD stimulant users are more likely to use other substances or to engage in risky behaviors.^{1, 6, 11-12, 14} Among high school students, nonmedical prescription stimulant users reported significantly higher rates of alcohol and other drug use than nonusers.¹² In a college-based survey, nonmedical prescription stimulant users were more likely to report use of alcohol, cigarettes, illegal drugs, and to engage in other risky behaviors.² Despite the growing evidence for nonmedical use of stimulants,

relatively little is known regarding the concurrent substance use patterns among adolescent who use prescription stimulants nonmedically.

In this study, we aimed to explore the subgroups of nonmedical adolescent ADHD stimulant users based on their concurrent problematic substance use using data from national surveys. We further examined variations in socio-demographic characteristics, mental health profiles, deviant behaviors, and service use among the empirically identified classes.

2. Methods

2.1 Study sample and measures

Combined annual data from the NSDUH public use data files for the years 2006 to 2011 (N= 338,495) were analyzed. The study sample was restricted to participants aged 12 to 17 (N=109,466) who reported using ADHD stimulants nonmedically in the past year (N=2,203). The NSDUH is an annual cross-sectional survey sponsored by the Substance Abuse and Mental Health Administration (SAMHSA) and is designed to provide estimates of the prevalence of alcohol and drug use in the household population of the United States, 12 years of age and older. The response rate for household screening ranged from 87% to 91% and for completed interviews from 74% to 76% across the 6 years. Survey items were administered by computer-assisted personal interviewing (CAPI) conducted by an interviewer and audio computer-assisted self-interviewing (ACASI) for sensitive questions. Detailed information about the sampling and survey methodology of the NSDUH can be found elsewhere.¹⁵⁻²⁰

2.1.1 Assessment of past-year nonmedical ADHD stimulant use—For the current analyses, ADHD stimulants were defined as stimulants with specific indications for treatment of ADHD, and included Ritalin® or methylphenidate, Cylert®, Dexedrine®, Dextroamphetamine, Adderall®, and Vyvanse®. The survey used the following question to assess lifetime nonmedical use of any ADHD stimulants: “Have you ever, even once, used Ritalin or methylphenidate that was not prescribed for you or that you took only for the experience or feeling it caused?” Nonmedical ADHD stimulant use was defined as past-year use if the time since last use was within the prior 12 months.

2.1.2 Assessment of socio-demographic characteristics—Socio-demographic variables included in the analyses were sex, age (12-13,14-15,16-17), race/ethnicity (non-Hispanic white, racial/ethnic minority), school dropout, average grade (C and above, D or lower) in the last period completed, and annual household income (\$19,999, \$20,000-\$34,999, \$35,000-\$69,999, \$70,000). These variables were chosen based on past research on correlates of substance use in adolescents.²¹

2.1.3 Assessment of past-year problematic substances use—Past-year problematic substance use was defined by fulfilling any of the criteria for past-year substance abuse or dependence based on the Diagnostic and Statistical Manual of Mental Disorders –IV (DSM-IV).²² The substances examined included alcohol, marijuana, cocaine, heroin, hallucinogens, inhalants, prescription opioids, and prescription tranquilizers/sedatives (combined).

2.1.4 Assessment of past-year mental health and deviant behavior variables—

Mental health variables included were past-year clinician-identified anxiety disorder or depression. Past-year mental health and substance use disorder (SUD) service use were ascertained by asking participants whether they received any mental health treatment or SUD treatment in the past year. Past-year deviant behaviors were ascertained by asking participants how many times they had attacked someone, sold drugs and stolen anything worth more than \$50 over the year. Consistent with past research,²³ participants who reported any of the three behaviors were categorized as having deviant behaviors (0 for none of these behaviors and 1 for 1 time or more). Past-year arrest was defined by having been arrested and charged with lawbreaking (not counting minor traffic violations; 0 for none and 1 for at least once). Past-year sexually transmitted disease (STD) was also assessed based on participant self-reports of diagnosis by a medical professional.

2.2 Statistical analyses

Complex latent class analysis (LCA)^{24,25} as implemented in the Mplus software²⁶ was used to identify subgroups according to concurrent problematic substance use among adolescents who reported using ADHD stimulants nonmedically in the past year. The LCA analysis was based on eight dichotomous substance use indicators (past-year problematic use of alcohol, marijuana, cocaine, heroin, hallucinogens, inhalants, prescription opioids, and tranquilizers/sedatives).

We performed LCA for 1 to 6 classes in order to ascertain the model with the optimal fit based on fit indices. Minimum values of the Bayesian Information Criterion (BIC) was given priority over other fit indices such as Akaike Information Criterion (AIC) and Sample Size Adjusted BIC (ABIC), given BIC's more stable performance in simulation studies.²⁷ We also considered the class size and clinical interpretability in selecting the model.

Once the number of classes was ascertained, correlates including socio-demographic characteristics, mental health and behavioral problems were incorporated into the models using unadjusted and adjusted multinomial regressions.²⁸ These analyses were conducted using a modal assignment latent regression approach with Stata 13.0 software.²⁹ A $p < 0.05$ was used to ascertain the statistical significance of findings.

3. Results

3.1 Subtypes of nonmedical ADHD stimulant users

Approximately 3.2% ($n = 2,203$) of adolescent participants from the NSDUH 2006 to 2011 reported nonmedical use of ADHD stimulants in the past year. The most commonly used substance among nonmedical ADHD stimulant users was problematic use of alcohol (53.3%), followed by problematic use of marijuana (47.9%), pain relievers (23.4%), hallucinogens (12.4%), tranquilizers and sedatives (9.9%), cocaine (7.3%), inhalants (5.8%) and heroin (1.7%). A 4-class model was chosen by taking into account the value of BIC as well as the clinical interpretability.²⁷ Figure 1 presents the prevalence of problematic use of different substances in the four classes of nonmedical ADHD stimulant users. Class 1 constituted 36.3% of the sample, and was comprised of individuals with low probabilities of

problematic use of alcohol and prescription opioids and near zero probabilities of other problematic substance use (*Low substance* class). Class 2 made up 14.8% of the study sample and included individuals with high probabilities of problematic use of alcohol and marijuana, moderate probabilities of problematic use of inhalants and hallucinogens, and with high probabilities of problematic use of pain relievers and sedatives/tranquilizers (*Prescription drug+* class). Class 3 included individuals with high probabilities of problematic use of marijuana and alcohol, and was the largest class (*Alcohol-marijuana* class, 41.2%). Finally, class 4 was comprised of individuals who had the highest probabilities of problematic use of most of the substances examined (*Multiple substance* class, 7.7%).

3.2 Characteristic of participants in the LCA-defined classes

Table 1 presents the socio-demographic, mental health, service use and deviant behavior profiles of the 4 classes of past-year nonmedical ADHD stimulant users. The *Prescription drug+*, *Alcohol-marijuana*, and *Multiple substance* classes showed particularly high prevalence of deviant behaviors (60.3%-85.5%) and arrest (23.6%- 34.2%). Furthermore, 46.4% of those in the *Prescription drug+* class reported past-year mental health service use and 27.1% reported a depression diagnosis.

Compared to the *Low substance* class, participants in all three other classes were more likely to report past-year depression (aORs=1.97 to 2.89), SUD treatment (aORs=2.97 to 7.30), deviant behaviors (aORs=4.80 to 14.52) and arrest (aOR=2.38 to 2.51). In addition, the adolescents in the *Prescription drug+* class were more likely to be female (aOR=1.69, 95% CI=1.16, 2.45) and adolescents in the *Alcohol-marijuana* class were typically older than those in the *Low substance* class (16-17 years age group compared to 12-13 years age group; aOR=3.84, 95% CI=1.53, 9.61).

4. Discussion

This study found that more than half of nonmedical adolescent ADHD stimulant users reported concurrent problematic substance use with the most frequently used substances being alcohol (53.3% of nonmedical ADHD stimulant users), marijuana (47.9%) and pain relievers (23.4%). We also found that with regard to concurrent problematic substance use, nonmedical ADHD stimulant users are a heterogeneous group encompassing four classes with distinct psychiatric and social profiles, which has implications for risk evaluation and preventive strategy development.

The classes that we labeled as *Prescription drug+*, *Alcohol-marijuana* and *Multiple substance* classes were generally more likely to report mental health problems, SUD service use, and deviant behaviors compared to the *Low substance* class, which had the lowest prevalence of concurrent problematic substance use. Similar to previous research,³⁰ our study points out that the association with mood disorders may be more pronounced in the subgroups that report more concurrent problematic substance use. Consistent with other studies that have shown individuals with co-occurring mental and substance disorders have higher rates of service use than those without co-occurring disorders,²³ a higher prevalence of SUD service use was also observed in the three classes identified in the present analyses.

Our finding underscores the significance of screening for mental health problems among the nonmedical ADHD stimulant users.

Despite the similarities among the three classes with a higher prevalence of concurrent substance use problems, especially with regard to psychiatric and behavior profiles, these three classes showed some differences in socio-demographic profiles. Most notably, participants in the *Prescription drug+ class* were more likely to be female compared to the *Low substance use class*, while the other two classes did not show such gender differences. As a recent review of studies of substance use in adolescents in the U.S. noted, adolescent girls are more likely to report nonmedical prescription opioids and tranquilizers use;³¹ our study further shows that adolescent girls are more likely to use these medications even among nonmedical stimulant users.

Comorbid substance use and psychiatric disorders confer additional risks not only for worse social outcomes but also for poorer SUD treatment response.^{32,33} Similarly, concurrent use of multiple substances is linked to more physical consequences and criminal involvement.³⁴ These considerations are especially relevant in the case of the *Multiple substance class*, who in addition to a greater burden of mental and substance use problems were also more likely to drop out of school. The findings call for a concerted effort to address mental health as well as substance use related problems in this vulnerable group of adolescents.

This study has multiple strengths, including a large sample size and generalizability to the US household population. However, this study has several limitations. First, all the information was based on self-report, which is prone to recall and reporting biases, although the validity of substance use reports in NSDUH has been previously established.³⁵ Second, the use of a cross-sectional design limits assessment of temporal relationships and causal inferences. Third, we used clinician-identified depression and anxiety in this study, which are subject to health service access and availability. Fourthly, the information regarding the frequency of nonmedical prescription stimulant use was not available, thus whether these subgroups differ by their level of severity remains unknown. Lastly, there is lack of information regarding the users' motivations, which could offer implications for prevention strategy development.

5. Conclusion

Our results suggest that adolescent nonmedical ADHD stimulant users are a heterogeneous group with distinct profiles with regard to concurrent substance use, socio-demographics and mental health profiles. Elucidating concurrent substance use patterns among adolescent stimulant users is crucial for identifying these subgroups and addressing their special needs.

Acknowledgments

Funding source:

This study was supported by K24 DA023186 (P.I.: Dr. Strain) and National Institute of Child and Human Development grant HD060072 (P.I.: Dr. Martins). NIDA and NICHD have no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

References

1. McCabe SE, Boyd CJ, Young A. Medical and nonmedical use of prescription drugs among secondary school students. *J Adolesc Health*. Jan; 2007 40(1):76–83. [PubMed: 17185209]
2. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. *Addiction*. Jan; 2005 100(1): 96–106. [PubMed: 15598197]
3. Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. *Pharmacotherapy*. Oct; 2006 26(10):1501–1510. [PubMed: 16999660]
4. Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. *Am J Psychiatry*. Jun; 2003 160(6):1071–1077. [PubMed: 12777264]
5. Drug Enforcement Administration. ARCOS 2: Report 1, Retail drug distribution. Department of Justice; 2003.
6. Arria AM, Caldeira KM, O'Grady KE, Vincent KB, Johnson EP, Wish ED. Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use. *Pharmacotherapy*. Feb; 2008 28(2):156–169. [PubMed: 18225963]
7. Garnier-Dykstra LM, Caldeira KM, Vincent KB, O'Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: four-year trends in exposure opportunity, use, motives, and sources. *J Am Coll Health*. 2012; 60(3):226–234. [PubMed: 22420700]
8. Johnston, LD.; O'Malley, PM.; Bachman, JG. College Students and Adults Ages 19–40. Washington, DC: 2003. Monitoring the Future National Survey Results on Drug Use, 1975–2002: II..
9. McCabe SE, West BT, Wechsler H. Trends and college-level characteristics associated with the non-medical use of prescription drugs among US college students from 1993 to 2001. *Addiction*. Mar; 2007 102(3):455–465. [PubMed: 17298654]
10. Arria AM, Wish ED. Nonmedical use of prescription stimulants among students. *Pediatr Ann*. Aug; 2006 35(8):565–571. [PubMed: 16986451]
11. Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. *Pediatrics*. Dec; 2006 118(6):2472–2480. [PubMed: 17142533]
12. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. *Subst Use Misuse*. Jun; 2004 39(7):1095–1116. [PubMed: 15387205]
13. Substance Abuse and Mental Health Services Administration. The DAWN Report: Emergency Department Visits Involving Attention Deficit/Hyperactivity Disorder Stimulant Medications. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; Rockville, MD: 2013.
14. McCabe SE, Cranford JA, Morales M, Young A. Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. *J Stud Alcohol*. Jul; 2006 67(4):529–537. [PubMed: 16736072]
15. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Rockville, MD: 2007. Results from the 2006 National Survey on Drug Use and Health: National Findings.. NSDUH Series H-32, DHHS Publication No. SMA 07-4293
16. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Rockville, MD: 2008. Results from the 2007 National Survey on Drug Use and Health: National Findings.. NSDUH Series H-34, DHHS Publication No. SMA 08-4343
17. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Rockville, MD: 2009b. Results from the 2008 National Survey on Drug Use and Health: National Findings.. NSDUH Series H-36, HHS Publication No. SMA 09-4434
18. Substance Abuse and Mental Health Services Administration. Summary of National Findings. Office of Applied Studies. Rockville, MD: 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I.. NSDUH Series H-38A, HHS Publication No. SMA 10-4856

19. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Rockville, MD: 2011. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings.. NSDUH Series H-41, HHS Publication No. SMA 11-4658
20. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Rockville, MD: 2012. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings.. NSDUH Series H-44, HHS Publication No. SMA 12-4713
21. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Rockville, MD: 2007. Use of Marijuana and Blunts among Adolescents: 2005.. NSDUH Series H-30, DHHS Publication No. SMA 06-4194
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed.. American Psychiatric Publishing; Washington, DC: 1994.
23. Chen LY, Crum RM, Martins SS, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. *Psychiatr Serv.* Sep 1; 2013 64(9):863–870. [PubMed: 23728427]
24. Hagenaars, JA.; McCutcheon, AL. Applied Latent Class Analysis. Cambridge University Press; New York: 2002.
25. Patterson BH, Dayton CM, Graubard BI. Latent Class Analysis of Complex Sample Survey Data: Application to Dietary Data. *JASA.* 2002; 97(459)
26. Mplus User's Guide. Sixth Edition [computer program]. Muthén & Muthén; Los Angeles, CA: 1998-2010.
27. Nylund KL, Asparoutiov T, Muthen BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. *Struct Equ Modeling.* 2007; 14(4):535–569.
28. Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical variables: One-step versus three-step estimators. *Polit Anal.* 2004; 12(1):3–27.
29. Stata Statistical Software: Release 13 [computer program]. StataCorp LP; College Station, TX: 2013.
30. Teter CJ, Falone AE, Cranford JA, Boyd CJ, McCabe SE. Nonmedical use of prescription stimulants and depressed mood among college students: frequency and routes of administration. *J Subst Abuse Treat.* Apr; 2010 38(3):292–298. [PubMed: 20129754]
31. Young AM, Glover N, Havens JR. Nonmedical use of prescription medications among adolescents in the United States: a systematic review. *J Adolesc Health.* Jul; 2012 51(1):6–7. [PubMed: 22727071]
32. Grant BF, Harford TC. Concurrent and simultaneous use of alcohol with cocaine: results of national survey. *Drug and alcohol dependence.* Feb; 1990 25(1):97–104. [PubMed: 2323315]
33. Hedden SL, Malcolm RJ, Latimer WW. Differences between adult non-drug users versus alcohol, cocaine and concurrent alcohol and cocaine problem users. *Addict Behav.* Mar; 2009 34(3):323–326. [PubMed: 19059733]
34. Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. *Clin J Pain.* Jul-Aug; 2002 18(4 Suppl):S14–27. [PubMed: 12479251]
35. Harrison, LD.; Martin, SS.; Enev, T.; Harrington, D. Comparing drug testing and self-report of drug use among youths and young adults in the general population. Substance Abuse and Mental Health Services Administration, Office of Applied Studies; Rockville, MD: 2007.

Highlights

More than half of nonmedical adolescent ADHD stimulant users reported concurrent problematic substance use.

Adolescent nonmedical ADHD stimulants users are a heterogeneous group with distinct classes with regard to concurrent substance use, mental health and behavioral problems.

Multiple substance class were significantly more likely to report mental health and behavioral problems, indicating their worse outcome and greater medical need.




Figure 1. Prevalence of problematic use of other substances in four classes of adolescents with past-year nonmedical ADHD stimulant use in the 2006–2011 National Survey on Drug Use and Health.

Table 1

Characteristics of past-year nonmedical ADHD stimulant users, by concurrent problematic substance use class in a sample of the US population aged 12-17 (N= 2,203): data from 2006-2011 National Survey on Drug Use and Health.

Characteristics, N (Wgt%)	Low substance class (n=784)	Prescription drug+ class (n=343)	Prescription drug+ class vs. Low substance class aOR (95% CI)	Alcohol marijuana class (n=896)	Alcohol-marijuana class vs. Low substance class aOR (95% CI)	Multiple substance class (n=180)	Multiple substance class vs. Low substance class aOR (95% CI)
Gender							
Male	376(48.0)	136(38.1)	1.00	474(52.3)	1.00	87(46.5)	1.00
Female	408(52.0)	207(61.9)	1.69(1.16,2.45)	422(47.7)	1.02(0.79,1.31)	93(53.5)	1.49(0.89,2.50)
Age							
12-13	87(11.1)	26(11.4)	1.00	17(2.3)	1.00	11(4.4)	1.00
14-15	226(19.9)	121(32.3)	0.84(0.38,1.85)	225(27.0)	2.65(0.97,7.21)	44(67.1)	1.31(0.40,4.31)
16-17	471(59.0)	196(56.4)	1.02(0.48,2.14)	654(70.7)	3.84(1.53,9.61)	125(68.5)	2.21(0.68,7.12)
Race							
Non-Hispanic White	595(77.6)	265(79.5)	1.00	725(83.3)	1.00	142(83.438)	1.00
Minorities	189(22.4)	78(20.5)	0.64(0.42,0.99)	171(16.7)	0.67(0.49,0.91)	38(16.6)	0.53(0.29,0.98)
School Dropout							
No	765(97.5)	324(95.3)	1.00	837(93.7)	1.00	162(89.5)	1.00
Yes	19(2.6)	19(4.7)	1.16(0.40,3.35)	59(6.3)	0.87(0.41,1.86)	18(10.5)	0.76(0.28,2.10)
Average Grade							
A,B, and C	713(91.2)	273(81.1)	1.00	759(86.2)	1.00	142(81.8)	1.00
D or lower	71(8.8)	70(18.9)	1.72(0.95,3.10)	137(13.8)	1.35(0.86,2.14)	38(18.2)	1.49(0.73,3.04)
Household Income							
<\$20,000	103(12.4)	69(19.6)	1.00	105(10.8)	1.00	33(18.9)	1.00
\$20,000-\$49,999	233(28.1)	111(33.6)	0.76(0.44,1.33)	331(34.4)	1.43(0.94,2.17)	59(26.6)	0.72(0.31,1.71)
\$50,000-\$74,999	140(15.8)	66(16.0)	0.67(0.35,1.30)	331(34.4)	1.13(0.67,1.91)	26(11.1)	0.68(0.30,1.56)
\$75,000	308(43.8)	97(30.8)	0.50(0.28,0.91)	308(39.2)	1.05(0.65,1.69)	62(43.4)	0.84(0.34,2.09)
Past-year depression							
No	667(91.9)	237(72.9)	1.00	723(85.0)	1.00	120(68.5)	1.00
Yes	72(8.1)	86(27.1)	2.89(1.86,4.48)	140(15.0)	1.97(1.25,3.10)	53(31.5)	2.76(1.41,5.40)
Past-year anxiety							
No	739(95.0)	291(86.8)	1.00	825(93.0)	1.00	144(75.6)	1.00
Yes	45(5.0)	52(13.2)	0.87(0.46,1.64)	71(7.0)	0.72(0.39,1.35)	36(24.4)	1.74(0.76,4.00)
Past-year mental health treatment							
No	601(78.6)	178(53.6)	1.00	646(72.9)	1.00	93(61.3)	1.00

Characteristics, N (Wgt%)	Low substance class (n=784)	Prescription drug+ class (n=343)	Prescription drug+ class vs. Low substance class aOR (95% CI)	Alcohol marijuana class (n=896)	Alcohol-marijuana class vs. Low substance class aOR (95% CI)	Multiple substance class (n=180)	Multiple substance class vs. Low substance class aOR (95% CI)
Yes	166(21.4)	157(46.4)	1.56(0.97,2.49)	241(27.1)	0.97(0.67,1.38)	85(38.7)	1.03(0.59,1.79)
Past-year SUD treatment							
No	754(96.8)	270(79.3)	1.00	769(85.9)	1.00	115(62.2)	1.00
Yes	30(3.3)	73(20.7)	3.45(2.13,6.93)	127(14.1)	2.97(1.60,5.46)	65(37.8)	7.30(3.73,14.27)
Past-year deviant behaviors							
No	572(73.3)	101(35.2)	1.00	355(39.7)	1.00	25(14.2)	1.00
Yes	212(26.7)	242(64.8)	4.80(3.08,7.50)	541(60.3)	3.75(2.84,4.94)	155(85.8)	14.52(8.19,25.74)
Past-year arrest							
No	718(92.7)	239(73.7)	1.00	686(76.4)	1.00	113(65.8)	1.00
Yes	66(7.3)	104(26.3)	2.38(1.31,4.33)	210(23.6)	2.51(1.56,4.04)	66(34.2)	2.50(1.29,4.83)
Past-year STD							
No	776(98.9)	333(97.4)	1.00	879(98.0)	1.00	169(95.5)	1.00
Yes	8(1.1)	10(2.6)	0.58(0.11,2.94)	17(2.0)	0.56(0.11,2.91)	11(4.5)	0.43(0.08,2.47)

Note: aOR stands for adjusted odds ratio, CI for confidence interval, SUD for substance use disorder and STD for sexually transmitted diseases.